Milagen has dedicated over 25 years to the research and development of innovative blood-based tests aimed at the early detection of cancer and its recurrence. The company has successfully developed and validated these tests through extensive studies involving thousands of patients, focusing on the five major cancers that account for nearly half of all cancer cases: breast, colorectal, lung, prostate, and ovarian cancer. By detecting blood-secreted markers at the early stages of cancer development, Milagen's tests empower patients and healthcare providers to implement preventive therapeutic measures, ultimately improving clinical outcomes.

Central to Milagen's approach is its proprietary proteome technology, which facilitates the discovery of key protein biomarkers associated with cancer. These biomarkers are rigorously validated for their sensitivity, specificity, and clinical utility, ensuring effective early-stage cancer detection. The company offers products like MammoCheck and IgoCheck, which are serum-based tests designed to monitor breast and colorectal cancer recurrence and therapy response, respectively. Additionally, Milagen is actively developing further tests for lung, ovarian, and prostate cancers, as well as a comprehensive four-in-one test for the early detection of primary cancer, reinforcing its commitment to advancing cancer management and surveillance.

United States

Milagen is a privately held, late-stage, pre-commercial diagnostic company focused on commercializing easy-to-use, non-invasive, in vitro diagnostic (IVD) products designed to fulfill unmet clinical needs in the prevention, detection, diagnosis, and management of major cancers. 
We are making the transition to commercialize our novel, proprietary antibody-based blood serum assays for detection of Breast and Colon cancer recurrence in a CLIA setting while we are preparing for a major clinical study to support an intended use for the early detection of major cancers. 

Milagen

Company Details